The FDA has approved clinical trials for organ transplants involving genetically modified pigs, initiated by biotech firms United Therapeutics Corp. and eGenesis. With over 106,000 people on the waiting list for transplants in the U.S., this innovation is seen as a crucial step forward. The United trial will start with six patients, potentially expanding to 50, while eGenesis has announced a study for three patients. Despite the promise, ethical and health concerns remain around xenotransplantation, especially regarding disease transmission and long-term impacts on patients.
The FDA's green light for kidney transplants from genetically modified pigs marks a significant advancement in addressing the organ shortage crisis in the United States.
These clinical trials may pave the way for wider acceptance and use of xenotransplantation, which has been growing rapidly with advances in gene-editing technology.
Collection
[
|
...
]